[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Agenus Inc (AGEN)

Agenus Inc (AGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,448
  • Shares Outstanding, K 38,398
  • Annual Sales, $ 114,200 K
  • Annual Income, $ 120 K
  • EBIT $ -20 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.60
  • Price/Sales 1.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 119.04% (-53.70%)
  • Historical Volatility 91.06%
  • IV Percentile 43%
  • IV Rank 7.94%
  • IV High 524.17% on 02/06/26
  • IV Low 84.12% on 08/04/25
  • Expected Move (DTE 11) 0.47 (12.17%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 146
  • Volume Avg (30-Day) 549
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 10,254
  • Open Int (30-Day) 8,263
  • Expected Range 3.37 to 4.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.95
  • Number of Estimates 2
  • High Estimate $2.10
  • Low Estimate $1.80
  • Prior Year $-1.03
  • Growth Rate Est. (year over year) +289.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.24 +18.52%
on 04/02/26
5.08 -24.41%
on 04/15/26
+0.44 (+12.94%)
since 04/01/26
3-Month
2.71 +41.70%
on 02/05/26
5.08 -24.41%
on 04/15/26
+1.00 (+35.21%)
since 01/30/26
52-Week
2.71 +41.70%
on 02/05/26
7.34 -47.68%
on 07/11/25
+0.98 (+34.27%)
since 05/01/25

Most Recent Stories

More News
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Four abstracts accepted across melanoma, colorectal cancer, and translational research

AGEN : 3.84 (-1.79%)
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Partnership enables timely access to botensilimab plus balstilimab through France’s government-reimbursed Autorisation d’Accès Compassionnel (AAC) pathway and paid named-patient programs (NPP) in...

AGEN : 3.84 (-1.79%)
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer

First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a...

AGEN : 3.84 (-1.79%)
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026

Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing, and durability of...

AGEN : 3.84 (-1.79%)
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Colorectal...

AGEN : 3.84 (-1.79%)
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET

AGEN : 3.84 (-1.79%)
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer

A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy

AGEN : 3.84 (-1.79%)
Agenus: Q4 Earnings Snapshot

Agenus: Q4 Earnings Snapshot

AGEN : 3.84 (-1.79%)
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL...

AGEN : 3.84 (-1.79%)
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access programs

AGEN : 3.84 (-1.79%)

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

3rd Resistance Point 3.99
2nd Resistance Point 3.93
1st Resistance Point 3.89
Last Price 3.84
1st Support Level 3.79
2nd Support Level 3.73
3rd Support Level 3.69

See More

52-Week High 7.34
Fibonacci 61.8% 5.57
Fibonacci 50% 5.03
Fibonacci 38.2% 4.48
Last Price 3.84
52-Week Low 2.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.